Based on the recommendations of the Chinese consensus guidelines for the diagnosis and treatment of gastrointestinal stromal tumours, except for patients with PDGFRA exon 18 D842V mutation, exon 9 mutation, and wild-type GIST, the remaining patients received imatinib 400 mg/day adjuvant therapy. The gene discussed is PDGFRA; the disease is gastrointestinal stromal tumor.